Clin Osteol 2016; 21(4): 124-135

Diagnosis and treatment of bone disease in multiple myeloma; I. Etiopathogenesis, clinical presentation and examination procedures in myeloma bone diseaseReview articles

V. ©čudla, J. Minařík, T. Pika, M. Heřman, M. Mysliveček

The article summarizes current knowledge about the etiopathogenesis of myeloma bone disease (MBD), including the association between the myeloma process and concomitant changes in the bone marrow environment as well as bone resorption induced by an imbalance between osteoclastic bone resorption and osteoblastic formation. In addition to an outline of the clinical presentation, the place of MBD in the diagnosis, differential diagnosis and stratification of multiple myeloma (MM) is discussed in the context of the updated International Myeloma Working Group diagnostic criteria. Considerable attention is paid to the role of conventional and specific benefit of modern imaging methods, in particular whole-body low-dose computed tomography, whole-body magnetic resonance imaging, 18FDG-positron emission tomography/computed tomography and 99mTc-MIBI skeletal scintigraphy. Also mentioned is the role of dual-energy X-ray absorptiometry and bone metabolism biomarker analysis in the assessment of the current state and development of BMD. Early recognition of BMD has not only diagnostic, differentially diagnostic and prognostic aspects but also a therapeutic benefit as it predetermines an individual approach to the treatment of both BMD and MM itself.

Keywords: myelomová kostní choroba, etiopatogeneze, klinický obraz, celotělová nízkodávkovaná výpočetní tomografie, celotělová magnetická rezonance, pozitronová emisní tomografie/výpočetní tomografie, dvouenergetic-

Published: December 11, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©čudla V, Minařík J, Pika T, Heřman M, Mysliveček M. Diagnosis and treatment of bone disease in multiple myeloma; I. Etiopathogenesis, clinical presentation and examination procedures in myeloma bone disease. Osteologický bulletin. 2016;21(4):124-135.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. International Myeloma Working Group. Criteria for the clasification of monoclo­ nal gammopathies, multiple myeloma and related disorders: a report national Myeloma Working Group. Brit J Haematol 2003; 121:749-757. Go to original source...
    2. Hájek R, Adam Z, ©čudla V, Maisnar V, Bačovský J, ©pička I, Krejčí M, Kess P, Minařík J, Sandecká V, Radocha J. Česká myelomová skupina. Souhrn dopo­ ručení 2012 "Diagnostika a léčba mnohočetného myelomu". Transf Hematol dnes 2012;18:1-89.
    3. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, Leleu X, Zweengman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, John HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BGM, San Miguel J. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-548. Go to original source...
    4. Roodman GD. Diagnosis and treatment of myeloma bone disease. In: Rajkumar SV, Kyle RATreatment of multiple myeloma Cambridge University Press 2009; p 64-75. Go to original source...
    5. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siege Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA and Durie BGM, on behalf of IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques diagnosis and monitoring of multiple myeloma. Leukemia 2009; 23:1545-1556. Go to original source...
    6. Terpos E, Politou M, Rahemtulla A New insights into the pathophysiology management of bone disease in multiple myeloma. Br J Haematol 2003; 123:758-769. Go to original source...
    7. Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ. IL-3 expression by myeloma cells increases both osteoclast formation growth of myeloma cells. Blood 2004;103:2308-2315. Go to original source...
    8. Walker RE, Lawson MA, Buckle CH, Snowden JA, Chantry AD. Myeloma bone disease: pat 111:117-138.
    9. Tsirakis G, Roussou P, Pappa CA, Kolovou A, Vasilokonstantaki Ch, Mimina Kyriakaki S. Increased serum levels of MIP-1 correlate with bone disease and angiogenic cytokines in patients with multiple myeloma. Med Oncol 2014; 31:778-782. Go to original source...
    10. Wang XT, He YCh, Zhou SY, Jiang J, Huang YM, Liang YZ, Lai YR. Bone mar­ row plasma macrophage inflammatory protein-1 (MIP-1) and sclerostin in mul­ tiple myeloma: relationship with bone disease and clinical characteristics Res 2014;38:525-531. Go to original source...
    11. Silbermann R, Bolzoni M, Storti P, Guasco D, Bonomini S, Zhou D, Wu J, Anderson JL, Windle JJ, Aversa F, Roodman GD, Giuliani N. Bone marrow monocyte -/ macrophage -derived activin A mediates the of IL-3 in multiple myeloma. Leukemia 2014;28:951-954. Go to original source...
    12. Andrews NA Multiple myeloma bone blasts. IBMS Bone Key 9 2012;50:1-3.
    13. Granger A, Carbone C, Izzo M, Grano M. Cellular mechanisms of multiple myelo­ ma bone disease. Clin Devel Immunol 2013. http://dx.doi.org/10.1155/2013/289458 Go to original source...
    14. Bam R, Ling W, Khan S, Pennisi A, Venkateshaiah US, Li X, van Rhee F, Usmani S, Barlogie B, Shaughnessy J, Epstein J, Yaccoby S. Role of Bruton's tyro kinase in myeloma cell migration and induction of bone disease. Am J Hematol 2013;88:463-471. Go to original source...
    15. Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E. Serum concentrations of Dickkopf-1 protein are in­ creased in patiens with multiple myeloma and redu transplantation. Int J Cancer 2006;119:1728-1731. Go to original source...
    16. Sezer G, Heider U, Zavrzli I, Kuhne CA, Hofbauer LC. RANK protegerin in myeloma bone disease. Blood 2003;101:2094-2098. Go to original source...
    17. Seidel C, Hjertner G, Abildgaard N, Heickendorff L, Hjorth M, Westin J, Nie JL, Hjorth-Hansen H, Waage A, Sundan A, Borset M. Nordic Myeloma Study Group. Serum osteoprotegerin levels are reduced in patiens with multiple myelo­ ma with lytic bone disease. Blood 2001;98:2269-2271. Go to original source...
    18. Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD, Giuliani N. IL-3 is a potential inhibitor of osteoblast differentia in multiple myeloma. Blood 2005;106:1407-1414. Go to original source...
    19. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr. The role of the Wnt-signaling antagonist DKK-1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-2494. Go to original source...
    20. Canalis E, Deregowski V, Ibreira RC, Gazzerro E. Signals that determine the of osteoblastic cells. J Endocrinol Incest 2005;28:3-7.
    21. Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 2010;28:244-250. Go to original source...
    22. Qiang YW, Chen Y, Stephens G, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteo­ protegerin and RANKL production of osteoblasts: a potential mechanism under­ lying osteolytic bone lesions in multiple myeloma. Blood 2008;112:196-207. Go to original source...
    23. Kaiser M, Mieth M, Liebisch P, Gberlander R, Rademacher J, Jakob C, Kleebe Fleissner C, Braendle E, Peters M, Stover D, Sezer G, Heider U. Serum concent­ rations of DKK-1 correlate with the extent o ple myeloma. Eur J Haematol 2008;80:490-494. Go to original source...
    24. Zhou F, Meng S, Song H, Claret FX. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic interventios. Blood 2013;27:261-267. Go to original source...
    25. Johnson SK, Stewart JP, Bam R, Qu P, Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S. CYR61/CCN1 overexpression in the myeloma microen­ vironment is associated with superior survival and reduced bone disease. Blood 2014;124:2051-2060. Go to original source...
    26. Roodman GD. CCN1: a sticky issue in myeloma. Blood 2014;124:2006-2007. Go to original source...
    27. Ruan J, Trotter TN, Nan L, Luo R, Javed A, Sanderson RD, Suva LJ, Yang Y. Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone 2013;57:10-17. Go to original source...
    28. Giuliani N, Ferretti M, Bolzoni M, Storti P, Lazzaretti M, Dalla Phlma B, Bonomini S, Martella E, Agnelli L, Neri A, Ceccarelli F, Palumbo C. Increased osteocyte death in multiple myeloma pa formation. Leukemia 2012;26:1391-1401. Go to original source...
    29. Johnson DC, Weinhold N, Mitchell J, Chen B, Stephens GW, Forsti A, Nic Kaiser M, Gregory WA, Cairns D, Jackson GH, Hoffmann P, Noethen MM, Hillengass J, Bertsch U, Barlogie B, Davis FE, Hemmin ki K, Goldschmidt H, Houlston RS, Morgan GJ. Genetic factors influencing the risk of multiple mye ma bone disease. Leukemia 2016; doi:10.1038/leu.2015.342 Go to original source...
    30. Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzch S, Raje N, Sezer G, García-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BGM, Roodman GD. International Myeloma Working Group reccommendations for the treatment of multiple myeloma-related bone disease. J Clin Gncol 2013;31:2347-2357. Go to original source...
    31. Mulligan M, Smith S, Talmi D. Whole body radiography for bone sur ning of cancer and myeloma patients. Cancer Invest 2008; 26: 916-922. Go to original source...
    32. Minařík J, Hrbek J, Pika T, Heřman M, Bačovský J, Mysliveček M, ©čudla V. Srovnání přínosu konvenčního RTG, celotělové magnetické rezonance a celo lového nízkodávkovaného CT v diagnostice myelomové kostní nemoci. Gsteol bulletin 2013;4:143-147.
    33. Minarik J, Hrbek J, Pika T, Novak M, Bacovsky J, Herman M, Hrabalek L, Frysakova L, Pusciznova P, Scudla V. X-Ray in multiple myel standard" any more: Case series. J Bone Mar Res 2014;2:1-4.
    34. Mysliveček M, Nekula J, Bačovský J. Zobrazovací vání mnohočetného myelomu. Vnitř Lék 2006;52:46-54.
    35. Heřman M, Hrbek J, ©čudla V, Bačovský J, Pika T, Minařík J. Korelace nál lotělového MR a stáľovacího systému Durie/Salmon u pacientů s monoklonální gamapatií nejistého významu a mnohočetným myelomem. Čs Radiol 2010;64: 203-212.
    36. Lutje S, De Rooy JWJ, Croockewit S, Koedam E, Gyen WJG, Raymakers RA Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therape­ utical evaluation of patients with multiple myeloma. Ann Hematol 2009;88:1161-1168. Go to original source...
    37. Kropil P, Fenk R, Fritz LB, Blondin D, Kobbe G, Modder U, Cohnen M. Comparison of whole-body 64-slice multidetector computed tomography and con­ ventional radiography in staging of multiple myeloma. European Radiol 2008; 18:51-58. Go to original source...
    38. Gleeson TG, Moriarty J, Shortt CP, Gleeson JP, Fitzpatrick P, Byrne B, McHugh G Connel M, G Gorman P, Eustace SJ. Accuracy of whole-body low-dose multi­ detector CT (WBLDCT) versus sceletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol 2009;38:225-236. Go to original source...
    39. Princewill K, Keyere S, Awan G, Mulligan M. Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey. Cancer Invest 2013; 31:206-211. Go to original source...
    40. Pianko MJ, Terpos E, Roodman D, Divgi CHR, Zweegman S, Hillengass J, Lentzsch S. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clin Cancer Res 2014;20: 5888-5897. Go to original source...
    41. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti G, Tosi P, Tacchetti P, Dangini D, Perrone G, Ceccolini M, Brioli A, Buttgnol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica Hematol J 2007; 92:50-55. Go to original source...
    42. Bauerle T, Hillengass J, Fechtner K, Zechmann CM, Grenacher L, Moehler TM, Christiane H, Barbara WG, Neben K, Kauczor HU, Goldschmidt H, Delorme S. Multiple myeloma and monoclonal gammopathy of undetermined significance: im­ portance of whole-body versus spinal MR imaging. Radiology 2009;252:477-485. Go to original source...
    43. Hillengass J, Langren G. Challenges and opportunities of novel imaging t ques in monoclonal plasma cell disorders: imaging "early myeloma". Leuk Lymphoma 2013;54:1355-1363. Go to original source...
    44. Maisnar V, Hájek R, Minařík J, Straub J, Pour L, Gregora E, Schutzová M. Diagnostika a léčba mnohočetného myelomu. Doplněk č. 2 z 6/2015. Transf Hematol dnes 2015;21:152-154.
    45. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff Sequential analysis of biochemical markers of bone resorption and bone densito­ metry in multiple myeloma. Haematologica 2004;89:567-577.
    46. Terpos F, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA. The com­ bination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with provement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22:2247-2256. Go to original source...
    47. Berenson JR. The use of bisphosphonates in patients with multiple myeloma.; 2012 Up ToDate. www.uptodate.com
    48. Mysliveček M, Bačovský J, ©čudla V, Koranda P, Minařík J, Buriánková E, Formánek R, Zapletalová J. 18FDG-PET/CT v diagnostice mnohočetného myelo­ mu a monoklonální gamapatie nejistého významu: srovnání s 99mTc-MIBI scintigrafií. Klin Gnkol 2010;23:325-331.
    49. Dankerl A, Liebisch P, Glatting G, Friesen C, Blumstein NM, Kocot D et al. Multiple myeloma: molecular imaging with 11C-methionine PET/CT-initial expe­ rience. Radiology 2007;242:498-508. Go to original source...
    50. Agool A, Schot BW, Jager PL, Vellenga E. 18F-FLT PET in hematologic disor­ ders: a novel technique to analyze the bone marrow compartment. J Nucl Med 2006;47:1592-1598.
    51. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol 2005; 184:1199-1204. Go to original source...
    52. Minařík J, Hrbek J, Mysliveček M, Puąčiznová P, Pika T, Bačovský J, Metelková I, Heřman M, ©čudla V. Racionální algoritmus zobrazovacích vyąetření u mnohočetného myelomu v podmínkách České republiky. Transfuze Hematol dnes 2015;21:200-205.
    53. Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, van de ICP, Heggelman BGF, Nievelstein RJ, Otten RHJ, van Lammeren-Venema, Ziljistra M, Arens AIJ, de Roy JW, Hoekstra OS, Raymakers R, Sonneveld P, Ostelo RW, Zweegman S. Comparison of modern and conventional imaging tech­ niques in establishing multiple myelomaview. Brit J Haematology 2013;162:50-61. Go to original source...
    54. Spira D, Weisel K, Brodoefel H, Schulze M, Kaufmann S, Horger M. Can whole­ body low-dose multidetector CT exclude the presence of myeloma bone dise patients with monoclonal gammopathy of undetermined significance (MGUS)? Acad Radiol 2012;19:89-94. Go to original source...
    55. Terpos E. Biochemic Treat Rev 2006;32:15-19. Go to original source...
    56. Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby Richardson P, Sonneveld P, Tricot G. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma tiens. Am J Hematol 2007;82:831-833. Go to original source...
    57. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau J-L, Anderson KC, Durie BGM on behalf of the Inter­ national Myeloma Working Group. The use of biochemical markers ofremodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010;24:1700-1712. Go to original source...
    58. Robbiani DF, Thesi M, Bergsagel PL. Bone tiple myeloma. N Engl J Med 2004;351:197-198. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.